QIPT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Quipt Home Medical Corp (QIPT) is not a good buy for a long-term beginner investor at this time. The acquisition deal at $3.65 per share, which is the current market price, limits any potential upside. Additionally, the stock will be delisted soon, reducing liquidity and transparency. While the company's revenue growth is strong, declining net income and EPS, along with the impending acquisition, make this stock unsuitable for the given investment scenario.
The stock is currently overbought with an RSI of 91.981, and the MACD is below 0, indicating a potential bearish divergence. However, moving averages are bullish, with SMA_5 > SMA_20 > SMA_200. The price is trading near its resistance levels (R1: 3.643, R2: 3.655), suggesting limited upside potential.
The acquisition by Kingswood Capital and Forager Capital is expected to enhance Quipt's competitiveness in the U.S. healthcare market and expand its service offerings.
The acquisition will result in delisting from major exchanges, reducing market transparency and liquidity. Additionally, the stock price is capped at $3.65 due to the acquisition agreement, limiting any further upside.
In Q1 2026, revenue increased by 31.96% YoY to $80,996,000, and gross margin improved by 6.10% YoY to 56.38%. However, net income dropped by -2.86% YoY to -$1,053,000, and EPS declined by -33.33% YoY to -$0.02, indicating profitability challenges.
Canaccord analyst Richard Close raised the price target to $3.65 from $2.30 and maintained a Hold rating. The updated model reflects the acquisition agreement, which caps the stock price at $3.65.
